Premium
Gemcitabine Delivery and Photodynamic Therapy in Cancer Cells via Porphyrin‐Ethylene‐Based Periodic Mesoporous Organosilica Nanoparticles
Author(s) -
Aggad Dina,
Jimenez Chiara Mauriello,
Dib Soraya,
Croissant Jonas G.,
Lichon Laure,
Laurencin Danielle,
Richeter Sébastien,
Maynadier Marie,
Alsaiari Shahad K.,
Boufatit Makhlouf,
Raehm Laurence,
Garcia Marcel,
Khashab Niveen M.,
GaryBobo Magali,
Durand JeanOlivier
Publication year - 2018
Publication title -
chemnanomat
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.947
H-Index - 32
ISSN - 2199-692X
DOI - 10.1002/cnma.201700264
Subject(s) - gemcitabine , photodynamic therapy , photosensitizer , materials science , mesoporous organosilica , porphyrin , in vivo , drug delivery , nanotechnology , cancer , mesoporous silica , chemistry , mesoporous material , medicine , photochemistry , organic chemistry , catalysis , microbiology and biotechnology , biology
Gemcitabine hydrochloride is an FDA‐approved chemotherapeutic drug used in the treatment of various cancers. Several drawbacks of gemcitabine, including its short in vivo half‐life of 8–17 min associated with a rapid excretion by the kidneys and its poor membrane permeability, have inspired research on a nanodelivery approach. In this study, we report ethylene‐based periodic mesoporous organosilica nanoparticles (PMOs) for photodynamic therapy and the autonomous delivery of gemcitabine in cancer cells. Porphyrins were used as photosensitizers and were localized in the walls of the PMOs while a high loading capacity of gemcitabine was observed in the porous structure. Depending on the nature of the photosensitizer, and its aggregation state, we were able to perform one or two‐photon photodynamic therapy. Two‐photon excited photodynamic therapy combined with gemcitabine delivery led to a synergy and a very efficient cancer cell killing.